Suggestions
Helen M. Boudreau
Board Member | Audit Committee Chair | Public Company CFO | Biotech/Pharma Executive
Helen M. Boudreau is a prominent figure in the biotechnology and pharmaceutical sectors, currently serving as a Board Member at Cara Therapeutics. She was appointed to the board on August 3, 2023, and brings extensive experience in financial leadership within the industry. Throughout her career, Boudreau has held significant roles including Chief Financial Officer (CFO) at various organizations such as Novartis Corporation, FORMA Therapeutics, and Proteostasis Therapeutics.123
Education and Early Career
Boudreau holds a Bachelor of Arts in Economics from the University of Maryland and an MBA from the Darden Graduate School of Business at the University of Virginia.23 Her career spans over 30 years, during which she has worked in finance, strategy, and operations across multiple sectors including pharmaceuticals and banking.3
Professional Accomplishments
- Chief Operating Officer: Previously served at the Bill & Melinda Gates Medical Research Institute.
- CFO Roles: Held CFO positions at Novartis Corporation in the U.S., global CFO for Novartis Oncology, and CFO for FORMA Therapeutics.
- Board Memberships: In addition to her role at Cara Therapeutics, she serves on the boards of Premier Inc. and other private biotechnology companies.34
Boudreau's expertise is particularly recognized in financial management and strategic planning within the biotech field, making her a valuable asset to the boards she serves on as they navigate complex industry challenges.
Highlights
